J Anesth Perioper Med. 2018;5(4):228-230. https://doi.org/10.24015/ebcmed.japm.2018.0073
From the Department of Anesthesia, Jewish Hospital, and Department of Anesthesiology & Perioperative Medicine, University of Louisville, Louisville, KY, USA.
Correspondence to Dr. Jiapeng Huang at jiapenghuang@yahoo.com.
EBCMED ID: ebcmed.japm.2018.0073 DOI: 10.24015/ebcmed.japm.2018.0073
Transcatheter aortic valve replacement (TAVR) has become the standard of care for prohibitive or high-risk patients with severe aortic stenosis. Due to excellent outcome results from TAVR, this technology has entered the intermediate risk patient population in the USA with Food and Drug Administration approval. The system has improved dramatically with much smaller sized sheath and better valve design over the years.
Article Type
Opinion
Declaration of Interests
The author declares no conflicts of interest.
Acknowledgements
This study was supported by the American Heart Association (grant 17GRNT33670387 to Dr. Wei Dong Gao).
This is an open-access article, published by Evidence Based Communications (EBC). This work is licensed under the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium or format for any lawful purpose. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.